|
|
|
|
Troels Koch博士
丹麥Santaris / Roche制藥公司首席技術(shù)官,研發(fā)副總裁
|
Ekkehard Leberer教授
法國賽諾菲研發(fā)聯(lián)盟管理高級總監(jiān), IMI COMPACT Consortium常務(wù)董事
|
Muthiah Manoharan博士
美國Alnylam制藥公司高級副總裁,新藥開發(fā)負(fù)責(zé)人
|
Brett Monia博士
美國Isis 制藥公司高級副總裁
Oligonucleotide Therapeutics Society當(dāng)選主席
|
Wed, Nov 5, 2014
|
||
Registration 13:00-18:00
|
||
|
||
Thu, Nov 06, 2014 (Day 1)
|
||
|
Chair
|
Mano Manoharan, PhD Senior Vice President, Alnylam Pharmaceuticals, USA
|
08:30-08:45
|
Introduction
|
CNAF Organizing Committee
|
08:45-09:30
|
Opening Keynote
|
Craig Mello, PhD Professor, University of Massachusetts Medical School, HHMI, 2006 Nobel Prize Winner, USA
Title: RNA-guided genome defense and new frontiers in biotech and medicine
|
09:30-10:10
|
Keynote
|
Brett Monia, PhD Senior Vice President, Isis Pharmaceuticals, OTS President, USA
Title: Transforming drug discovery for human therapeutics with antisense technology
|
10:10-10:35
|
Plenary
|
Judy Lieberman, MD, PhD Professor, Program Chair, Harvard Medical School, USA
Title: Targeted gene knockdown to treat cancer
|
10:35-10:55
|
Tea Break
|
|
10:55-11:20
|
Plenary
|
Matthew Porteus, MD, PhD Professor, Stanford School of Medicine, CRISPR Therapeutics Founder, USA
Title: Genome editing using engineered nucleases
|
11:20-11:45
|
Plenary
|
Erwei Song, MD, PhD Professor and Vice Dean, Sun Yat-Sen Memorial Hospital, China
Title: BRMS1L suppresses breast cancer metastasis by inducing epigenetic silence of FZD10
|
11:45-12:00
|
Technology
|
Rick Hogrefe, PhD Founder, President and Chief Executive Officer, TriLink BioTechnologies
Title: Designing a mRNA therapeutic suitable for scale up
|
12:00-13:30
|
Lunch
|
|
13:30-13:35
|
Chair
|
Brett Monia, PhD Senior Vice President, Isis Pharmaceuticals, OTS President, USA
|
13:35-14:15
|
Keynote
|
Troels Koch, PhD Senior Vice President and Chief Technology Officer, Santaris / Roche, Denmark
Title: LNA antisense – concepts & status
|
14:15-14:40
|
Plenary
|
Dmitry Samarsky, PhD Executive Vice President, Technology Development, RiboBio, China
Title: In vivo delivery of therapeutic oligonucleotides and potential applications for cancer
|
14:40-15:05
|
Plenary
|
Georg Sczakiel, PhD Professor, University of Lübeck, Germany
Title: Target RNA is involved in guide strand loading of Argonaute-2 and siRNA-induced RNA interference
|
15:05-15:25
|
Tea Break
|
|
15:25-15:50
|
Plenary
|
Peixuan Guo, PhD Professor, William S. Farish Fund Endowed Chair, University of Kentucky, USA
Title: A new generation of drugs from the emerging field of RNA nanotechnology
|
15:50-16:15
|
Plenary
|
Yi Jin, PhD Executive Vice President, Suzhou Ribo Life Science, China
Title: RNAi based therapeutics for Hepatitis B
|
16:15-16:30
|
Technology
|
Suresh Srivastava, PhD Founder and President, ChemGenes, USA
Title: BMEG oligonucleotides for efficient cellular delivery for therapeutic and molecular biological applications
|
16:30-16:55
|
Plenary
|
David Lewis, PhD Chief Scientific Officer, Arrowhead Research Corporation, USA
Title: Using Dynamic Polyconjugate® (DPC) technology to advance RNAi-based therapeutics
|
16:55-17:00
|
Day End
|
CNAF Organizing Committee
|
Fri, Nov 07, 2014 (Day 2)
|
||
09:00-09:05
|
Chair
|
Troels Koch, PhD Senior Vice President and Chief Technology Officer, Santaris / Roche, Denmark
|
09:05-09:45
|
Keynote
|
Ekkehard Leberer, PhD Professor, Senior Director of R&D Alliance Management, Sanofi, Germany
Title: Nucleic acid therapeutics: opportunities and challenges for innovation in drug development
|
09:45-10:10
|
Plenary
|
William Marshall, PhD President and Chief Executive Officer, Board Director, miRagen Therapeutics, USA
Title: Discovery and development of microRNA targeting therapeutics
|
10:10-10:35
|
Plenary
|
Micky Tortorella, PhD Chief Technology Officer and Vice President for Drug Discovery and Technology Transfer, Guangzhou Institutes of Biomedicine and Health, China
Title: Intra-articular delivery of siRNA-conjugates as new disease modifying osteoarthritis drugs
|
10:35-10:55
|
Tea Break
|
|
10:55-11:20
|
Plenary
|
Chengyu Jiang, PhD Professor, Chair, Peking Union Medical College, CAMS, China
Title: Hsa-miR-1246, hsa-miR-320a and hsa-miR-196b-5p inhibitors can reduce the cytotoxicity of Ebola virus glycoprotein in vitro
|
11:20-11:45
|
Plenary
|
Marc Lemaitre, PhD Chief Executive Officer, Sirnaomics, USA / China
Title: Improving siRNA therapeutics using polymer-nanoparticle (PNP) delivery: recent pre-clinical results with STP705 against skin scars
|
11:45-12:00
|
Technology
|
Kimo Sanderson Vice President, Asahi Kasei, Japan
Title: Therapeutic oligonucleotides from discovery to development: the importance of proper production and scale up
|
12:00-13:30
|
Lunch
|
|
13:30-13:35
|
Chair
|
William Marshall, PhD President, Chief Executive Officer, Board Director, miRagen Therapeutics, USA
|
13:35-14:15
|
Keynote
|
Mano Manoharan, PhD Senior Vice President, Alnylam Pharmaceuticals, USA
Title: Chemical strategies for systemic delivery of RNAi drugs
|
14:15-14:40
|
Plenary
|
Dirk Haussecker, PhD Founder and Curator, RNAi Therapeutics Blog, Germany
Title: RNA therapeutics emerging as major drug discovery engine
|
14:40-15:05
|
Plenary
|
TBD
|
15:05-15:20
|
Technology
|
Carina Andersson, PhD Marketing Head, GE, USA
Title: A manufacturing solution of oligonucleotides
|
15:20-15:40
|
Tea Break
|
|
15:40-16:05
|
Plenary
|
Sven Klussmann, PhD Chief Scientific Officer, NOXXON Pharma, Germany
Title: From bench to bedside – the conversion of mirror-image oligonucleotides into therapeutics
|
16:05-16:30
|
Plenary
|
Ryszard Kole, PhD Distinguished Scientist, Professor, Sarepta Therapeutics, USA
Title: Eteplirsen, a phosphorodiamidate morpholino oligonucleotide, as treatment for Duchenne muscular dystrophy (DMD)
|
16:30-16:55
|
Plenary
|
René Thürmer, PhD Deputy Head of the Unit Pharmaceutical Biotechnology, BfArM - Federal Institute for Drugs and Medical Devices, Germany
Title: Regulatory aspects of nucleic acids therapeutics
|
16:55-17:15
|
Closing Remarks
|
Craig Mello, PhD Professor, University of Massachusetts Medical School, HHMI, 2006 Nobel Prize Winner, USA
|
|
|
|
|
贊助咨詢: |
注冊及其他咨詢: |